Advertisement

Topics

Companies Related to "hu14.18-Interleukin-2 Fusion Protein in Treating Young Patients With Recurrent or Refractory Neuroblastoma" [Most Relevant Company Matches] RSS

13:42 EST 23rd February 2019 | BioPortfolio

Here are the most relevant search results for "hu14.18-Interleukin-2 Fusion Protein in Treating Young Patients With Recurrent or Refractory Neuroblastoma" found in our extensive corporate database of over 50,000 company records.

Showing "hu14 Interleukin Fusion Protein Treating Young Patients With" Companies 1–25 of 5,100+

Relevant

Globe Laboratories

Globe Labs manufactures and sells high quality, low cost human therapeutic proteins, human growth hormones, enzymes, research laboratory cytokines, chemokines & their respective inhibitors/antagonists for research and veterinary use. We are also manufacturers of bulk quantities for other pharmaceutical companies worldwide. Globe Labs is proud to have the largest antagonist product list in the worl...


Fusion Antibodies Ltd

Fusion, established in 2001 as a spin-out from Queen’s University Belfast, has won a host of awards for its leading-edge technology platform FET (Fusion Expression Technology). This enabling technology accelerates the validation of targets from DNA sequence through to recombinant protein expression. Fusion generates target specific antibodies from protein antigens with capability, through its an...

Practice Fusion Inc.

Practice Fusion addresses the complexities and critical needs of today's healthcare environments by providing a revolutionary free, web-based electronic health record (EHR) application and delivery model for physicians and patients. As a result, Practice Fusion is the fastest growing EHR community in the country for physicians. Practice Fusion has more than 21,000 users in 50 states. For more info...


Kareo

Practice Fusion provides a free, web-based Electronic Health Record (EHR) system to physicians. With charting, scheduling, e-prescribing, billing, lab integrations, unlimited support and a Personal Health Record for patients, Practice Fusion's EHR addresses the complex needs of today's healthcare providers and disrupts the health IT status quo. Practice Fusion is the fastest growing EHR community ...

Practice Fusion

Practice Fusion is the leading cloud-based electronic health record (EHR) platform for doctors and patients in the U.S., with a mission of connecting doctors, patients and data to drive better health and save lives. By facilitating over five million patient visits a month with more than 600 connected partners, Practice Fusion helps coordinate care within t...

Fusion Pharmaceuticals

Fusion Pharmaceuticals is a new pharmaceutical company located in Hamilton, Ontario, Canada focused on becoming the leader in the targeted alpha therapy field. Fusion will exploit its unique expertise in linking medical isotopes to targeting molecules to create highly effective therapeutics. In addition to its lead program, FPX-01, Fusion is building a pip...

Fusion Pharmaceuticals, Inc.

Fusion Pharmaceuticals is a clinical-stage biopharmaceutical company located in Hamilton, Ontario, Canada focused on becoming the leader in the targeted alpha therapy field. Fusion will exploit its unique expertise in linking medical isotopes to targeting molecules to create highly effective therapeutics. In addition to its lead program, FPX-01 with a clin...

Interleukin Genetics, Inc.

Interleukin Genetics, Inc. (OTCQB: ILIU) develops and markets proprietary genetic tests for chronic diseases and health related conditions. The products empower individuals to prevent certain chronic conditions and manage their existing health and wellness through genetic-based insights with actionable guidance. Interleukin Genetics leverages its resear...

Interleukin Genetics, Inc.

Interleukin Genetics, Inc. (OTCQB: ILIU) develops and markets a line of genetic tests under the Inherent Health® brand. The products empower individuals to prevent certain chronic conditions and manage their existing health and wellness through genetic-based insights with actionable guidance. Interleukin Genetics leverages its research, intell...

Life Sciences Ontario

Fusion Pharmaceuticals is a biopharmaceutical company located in Hamilton, Ontario, focused on becoming the leader in the targeted alpha therapy field. Fusion, which is a spin out from McMaster University’s Centre for Probe Development and Commercialization (CPDC), exploits its unique expertise in linking medical isotopes to targeting molecules to cre...

BioHesion Inc.

BioHesion is pleased to offer a custom cloning and protein expression service. We recognize a large number of applications exist for Gold Binding Fusion proteins. We believe that our technology provides a superior method to achieve high affinity binding, retain biological activity, and optimal orientation for fusion proteins. If your R&D, application or device would benefit from this technology.

Fusion Advertising

Fusion Advertising is a boutique agency and creative factory based in Dallas, TX. Formed in 2004, Fusion blends key staff members from diverse creative, media, logistics, financial and entrepreneurial backgrounds. The company can be found on the web at http://www.fusionista.com.

Altus Pharmaceuticals Inc.

Altus® Pharmaceuticals is focused on developing and commercializing novel protein therapeutics for patients with chronic gastrointestinal and metabolic diseases. Altus' in-depth knowledge of protein crystallization has resulted in a proprietary pipeline of orally-delivered and injectable protein replacement products. As a company, we are committed to improving the quality of life of patients.

Proteostasis Therapeutics

Proteostasis Therapeutics is discovering “Proteostasis Regulators” (PRs), small molecule drugs that restore proper protein function to treat neurodegenerative, metabolic, genetic and inflammatory disorders. The Proteostasis Network (PN) is the cellular machinery responsible for protein folding, trafficking and clearance, and it can become imbalanced ...

BioClin Therapeutics, Inc.

BioClin Therapeutics, Inc. is a privately-held clinical stage drug development company developing biologics to address medical conditions in areas of high unmet need. The company’s lead candidate is B-701, a potential first-in-class human monoclonal antibody targeting FGFR3 (fibroblast growth factor receptor 3). B-701 is currently being evaluated in t...

Proteostasis Therapeutics and Elan Corporation

Proteostasis Therapeutics is developing “Proteostasis Regulators” (PRs), small molecule drugs that restore proper protein function or remove misfolded and aggregated proteins to treat neurodegenerative, metabolic, genetic and inflammatory disorders. The Proteostasis Network is the cellular machinery responsible for protein folding, trafficking and ...

Providence Medical Technology, Inc.

Providence Medical Technology is a privately held medical device company developing minimally invasive solutions addressing the $1 billion worldwide cervical fusion market. The company is commercializing the DTRAX platform of cervical devices, which are used to provide indirect decompression and fusion in patients suffering from cervical radiculopat...

Centinel Spine, Inc.

STALIF MIDLINE™ is the latest in a series of anterior fusion devices developed, marketed and sold by Centinel Spine, Inc. Founded in 2008, Centinel Spine, Inc. is an innovative spinal device company committed to the design and development of simple, biomechanically sound solutions for spinal stabilization and fusion. The company is recognized as a lea...

med fusion

Headquartered in Lewisville, Texas, med fusion is an integrated, advanced laboratory and clinical trials service organization providing support to healthcare providers, biotech and pharmaceutical companies, through a patient-centric support model. The company’s 130,000-square foot facility includes a clinical laboratory, with a dedicated test developm...

ProteoTech Inc.

ProteoTech is a privately-held, drug development company that utilizes its amyloid expertise to discover and develop new drugs for treating misfolded protein disorders and amyloid diseases. ProteoTech’s lead small molecule drug, Systebryl™ (PTI-110), will soon be entering a Phase 1/2 proof-of-concept clinical trial in patients with AL (immunoglobulin ...

Fusion Sleep

Fusion Sleep (www.fusionsleep.com) restores health and increases quality of life for people suffering with sleep related disorders. Effective treatments enhance daytime function and energy, prevent chronic diseases and reduce risk for major accidents; commonly associated with sleep disorders. The Sleep Medicine Program services thousands of patients in Georgia, through locations in Metro Atlanta....

Young Survival Coalition (YSC)

Young Survival Coalition, based in New York City with nearly 30 national affiliates, is the premier international organization dedicated to the critical issues unique to young women and breast cancer. YSC offer resources, connections and outreach so women feel supported, empowered and hopeful. Through action, advocacy and awareness, YSC seeks to educate an...

Automated Fusion Technology Pty Ltd

Automated Fusion Technology Pty Ltd ( AFT ) was established in July 1991 as a design, manufacturing and service organisation specialising in automated fusion equipment. In addition to supplying a wide range of standard fusion machines and options, AFT provides a customised service which designs and builds equipment to meet clients' needs. The range of products includes service contracts, customise...

MacKenzie Young Advisors

MacKenzie Young Advisors provides discerning families financial confidence through a highly disciplined approach. MacKenzie Young Advisors was founded in 2008 by Scott MacKenzie, CFP®, CIMA and Jeff Young, CFA, two former Senior Vice Presidents/Private Wealth Advisors and 15 year veterans of SunTrust. MacKenzie Young Advisors, a private boutique financi...

Ocular Surface Center, P.A.

Ocular Surface Foundation (OSF) is a non-profit public medical research foundation (501c3) established in 1999, and carries s single mission of promoting the spread of the knowledge and skills that are important for treating ocular surface diseases. Under the leadership of the President, Billy K. Yeh, M.D., Ph.D., OSF supports research and educational programs that may create a differentiable valu...


More From BioPortfolio on "hu14.18-Interleukin-2 Fusion Protein in Treating Young Patients With Recurrent or Refractory Neuroblastoma"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks